Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pharmacokinetics

Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients

Abstract

Tacrolimus is an immunosuppressant commonly used in the prevention of graft-versus-host disease (GVHD) following allogeneic HCT. Unfortunately, the use of tacrolimus is associated with variable immunosuppression and toxicity. The purpose of this study was to describe tacrolimus population pharmacokinetic parameters, to identify relationships between clinical covariates and pharmacokinetic estimates, and to develop a model to predict tacrolimus clearance in HCT patients. Steady-state whole blood tacrolimus concentrations (n = 1625) obtained during intravenous and oral therapy were analyzed in 122 patients. Population clearance (CL) was 5.22 l/h and bioavailability (F) was 0.28. The influence of clinical covariates on population estimates of CL and F of tacrolimus were tested with nonlinear mixed effects models (NONMEM). CL was significantly reduced by elevations in total bilirubin 2.0–9.9 mg/dl (CL * 0.797), bilirubin 10 mg/dl (CL * 0.581), serum creatinine 2 mg/dl (CL * 0.587), grade III/IV graft-versus-host disease (CL * 0.814) and veno-occlusive disease (CL 0.814). No covariates were predictive of oral F. The interindividual variabilities in CL and F were 33% and 44%, respectively. Residual variability was 27.5% and 16.8% at tacrolimus concentrations of 10 μg/l and 20 μg/l, respectively. These models may be used to predict tacrolimus clearance and doses in adult patients following HCT. Bone Marrow Transplantation (2001) 28, 753–758.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Fay JW, Nash RA, Wingard JR et al. FK 506-based immunosuppression for prevention of graft-versus-host disease after unrelated donor marrow transplantation Transplant Proc 1995 27: 1374

    CAS  PubMed  Google Scholar 

  2. Fay JW, Wingard JR, Antin JH et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation Blood 1996 87: 3514–3519

    CAS  PubMed  Google Scholar 

  3. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study Blood 1995 85: 3746–3753

    CAS  PubMed  Google Scholar 

  4. Nash RA, Pineiro LA, Storb R et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors Blood 1996 88: 3634–3641

    CAS  PubMed  Google Scholar 

  5. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation Blood 1996 88: 4383–4389

    CAS  PubMed  Google Scholar 

  6. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 1998 92: 2303–2314

    CAS  PubMed  Google Scholar 

  7. Uberti JP, Silver SM, Adams PT et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies Bone Marrow Transplant 1997 19: 1233–1238

    Article  CAS  Google Scholar 

  8. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors Blood 2000 96: 2062–2068

    CAS  PubMed  Google Scholar 

  9. Plosker GL, Foster RH . Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation Drugs 2000 59: 323–389

    Article  CAS  Google Scholar 

  10. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus Clin Pharmacokinet 1995 29: 404–430

    Article  CAS  Google Scholar 

  11. Boswell GW, Bekersky I, Fay J et al. Tacrolimus pharmacokinetics in BMT patients Bone Marrow Transplant 1998 21: 23–28

    Article  CAS  Google Scholar 

  12. Mehta P, Beltz S, Kedar A et al. Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation Bone Marrow Transplant 1999 24: 1323–1327

    Article  CAS  Google Scholar 

  13. Woo M, Przepiorka D, Ippoliti C et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation Bone Marrow Transplant 1997 20: 1095–1098

    Article  CAS  Google Scholar 

  14. Wingard JR, Nash RA, Przepiorka D et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation Biol Blood Marrow Transplant 1998 4: 157–163

    Article  CAS  Google Scholar 

  15. Przepiorka D, Devine S, Fay J et al. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation Bone Marrow Transplant 1999 24: 1053–1056

    Article  CAS  Google Scholar 

  16. Devine SM, Geller RB, Lin LB et al. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis Biol Blood Marrow Transplant 1997 3: 25–33

    CAS  PubMed  Google Scholar 

  17. Koehler MT, Howrie D, Mirro J et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation Bone Marrow Transplant 1995 15: 895–899

    CAS  PubMed  Google Scholar 

  18. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome New Engl J Med 1996 334: 494–500

    Article  CAS  Google Scholar 

  19. Devine SM, Newman NJ, Siegel JL et al. Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation Bone Marrow Transplant 1996 18: 569–572

    CAS  PubMed  Google Scholar 

  20. Boeve BF, Kimmel DW, Aronson AE, de Groen PC . Dysarthria and apraxia of speech associated with FK-506 (tacrolimus) Mayo Clin Proc 1996 71: 969–972

    Article  CAS  Google Scholar 

  21. Steg RE, Kessinger A, Wszolek ZK . Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation Bone Marrow Transplant 1999 23: 959–962

    Article  CAS  Google Scholar 

  22. Grenier FC, Luczkiw J, Bergmann M et al. A whole blood FK 506 assay for the IMx analyzer Transplant Proc 1991 23: 2748–2749

    CAS  PubMed  Google Scholar 

  23. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation (second of two parts) New Engl J Med 1975 292: 895–902

    Article  CAS  Google Scholar 

  24. Beal L, Sheiner L . NONMEM User Guide San Francisco, CA, NONMEM Project Group, UCSF 1992

    Google Scholar 

  25. Przepiorka D, Blamble D, Hilsenbeck S et al. Tacrolimus clearance is age-dependent within the pediatric population Bone Marrow Transplant 2000 26: 601–605

    Article  CAS  Google Scholar 

  26. Lampen A, Christians U, Guengerich FP et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability Drug Metab Dispos 1995 23: 1315–1324

    CAS  PubMed  Google Scholar 

  27. Nakazawa Y, Chisuwa H, Ikegami T et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation Transplantation 1998 66: 1089–1093

    Article  CAS  Google Scholar 

  28. Sattler M, Guengerich FP, Yun CH et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat Drug Metab Dispos 1992 20: 753–761

    CAS  PubMed  Google Scholar 

  29. Vincent SH, Karanam BV, Painter SK, Chiu SH . In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism Arch Biochem Biophys 1992 294: 454–460

    Article  CAS  Google Scholar 

  30. Sato S, Fuchinoue S, Tojimbara T et al. Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients Transplant Proc 1998 30: 1274–1275

    Article  CAS  Google Scholar 

  31. Liu WT, Ren Y, Wang J, Wong PY . In vitro generation of tacrolimus metabolites and their detection in whole blood Transplant Proc 1998 30: 1454–1456

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobson, P., Ng, J., Ratanatharathorn, V. et al. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 28, 753–758 (2001). https://doi.org/10.1038/sj.bmt.1703224

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703224

Keywords

This article is cited by

Search

Quick links